Eli Lilly, Novo Nordisk Reveal India Weight-Loss Drug Strategies as Patent Expiry Looms

Overview

Eli Lilly and Novo Nordisk, makers of leading weight-loss drugs Mounjaro and Wegovy, have outlined their strategies for the Indian market. Ahead of semaglutide's patent expiry in March, the companies are focusing on pricing, market expansion through partnerships with Cipla and Emcure, and defending their products against anticipated cheaper generics.